with promising clinical improvement). We are currently engaged in a study to pursue this issue in a more scientific manner, and welcome the views of other clinicians.


S. Reutens, D. Castle Mills Street Clinical Research Unit, 35 Mills Street, Bentley, WA 6102, Western Australia

Genetic polymorphism and drug-induced movement disorders

Sir: We were interested to read the paper by Armstrong et al (1997) on drug-induced movement disorders in relation to the CYP2D6 genotype. We would agree that this important polymorphism may well be a contributory factor in more chronic drug-induced movement disorders.

Several lines of evidence support this. Firstly, one of the most robust findings in the whole field of tardive dyskinesia (TD) research is the link between TD and high neuroleptic dosage. Impaired clearance of antipsychotics due to the poor metaboliser genotype leads to elevated plasma levels, which has clear implications in view of the first association. Other studies have attempted to assess the problem from a different standpoint: looking at the variation in neuroleptic breakdown between those with TD and schizophrenic controls. The best study in this area is that of Yesavage et al (1987), which found a significant difference in standardised thioxanthine levels between 21 TD sufferers and 20 controls.

In our recent study (Bates, 1997) we used promethazine, a phenothiazine predominantly metabolised by the CYP2D6 cytochrome, to probe metabolic clearance in 18 patients, 10 with TD and eight controls. We used a high-performance liquid chromatography technique which simultaneously assayed promethazine and its two major breakdown products, the sulphoxide and monodesmethyl metabolites. We found evidence of a significant impairment of metabolism of promethazine in the TD group, with raised promethazine levels and raised promethazine to metabolite ratios, indicating this was not an effect of varying absorption or bioavailability. We will be publishing our results more fully soon.

This simple and relatively inexpensive method may prove useful in pretreatment testing to enable prediction of those likely to develop TD or concentration-dependent side-effects, and to guide dosage decisions.


G. D. I. Bates Birmingham Children's Hospital, Ladywood Middleway, Ladywood, Birmingham B16 8ET
A. E. van Woerkom, O. Lopes Queen Elizabeth Psychiatric Hospital, Mindelsohn Way, Birmingham B15 2TZ
R. Waring, L. Klovrz University of Birmingham, Edgbaston, Birmingham

Demography and age at onset of schizophrenia

Sir: Jablensky & Cole (1997) conclude from their analysis of the WHO 10-Country study of schizophrenia that marital status has a major effect on age at onset of schizophrenia, and that the effect of gender disappears when controlling for marital status (and other variables). However, these findings are partly due to demographic effects. To explain this artefact assume that outbreak of schizophrenia occurs (like a random event) irrespective of marital status. As is well known, married people are in our population on average older than single ones. Therefore the mean age at onset of schizophrenia will be later for married people than for single ones. This difference does not reflect a real association between schizophrenia and marriage (which was excluded by the hypothetical model) but it reflects a trivial demographic effect due to the different age structures of married and single people. This applies to men and women but in a different way. In general, women marry earlier than men. Thus, in the population, married women are on average younger than married men, and unmarried women are younger than unmarried men. Let us assume that outbreak of schizophrenia is related neither to gender nor to marital status. Then because of these different age structures the mean age at onset will be earlier for married women than for married men. The same relation holds for singles. But, as above, these differences are due to a trivial demographic effect. If there is a real association between gender and schizophrenia in the sense that onset is later for women, then this difference is reduced when comparing married women with married men and single women with single men. Thus differences in the age structures between married and single persons in the population explain, at least in part, the effects of marital status and gender on age at onset, described by Jablensky & Cole. The differences in age at onset between developing and developed countries may be attributed to different demographic structures in these countries. We do not deny these effects, but to disentangle demographic effects from real effects the age structures of the underlying population must be taken into account when analysing the data.


C. Jennen-Steinmetz, W. Löffler, H. Häfner Central Institute of Mental Health, J. 5, 68159 Mannheim, Germany

Author’s reply: Jennen-Steinmetz et al suggest that “differences in the age structures between married and single persons . . . explain, at least in part, the effects of marital status and gender on age at onset, described by Jablensky & Cole”. Since the statistical analyses we use uncorrelate gender and marital status prior to examining the relationship of either variable to age at onset, Steinmetz et al, can rest assured that no part of our conclusions reflects a spurious correlation between marital status and age at onset of schizophrenia that is induced by those two variables’ common association with gender differences in age at marriage. In the general linear model, the effects of gender (and gender-correlated differences in age at marriage) are partialed out, or controlled for, in the calculus underlying multiple regression (Mosteller & Tukey,
Genetic polymorphism and drug-induced movement disorders.

G D Bates, A E van Woerkom, O Lopes, R Waring and L Klovrza


Access the most recent version at DOI: 10.1192/bjp.170.5.485a

References

This article cites 0 articles, 0 of which you can access for free at:
http://bjp.rcpsych.org/content/170/5/485.1.citation#BIBL

Reprints/permissions

To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at

http://bjp.rcpsych.org/letters/submit/bjpcpsych;170/5/485a

Downloaded from

http://bjp.rcpsych.org/ on June 26, 2017

Published by The Royal College of Psychiatrists

To subscribe to The British Journal of Psychiatry go to:
http://bjp.rcpsych.org/site/subscriptions/